Mineralys Therapeutics (MLYS) CMO exercises options, sells 417 shares in plan trade

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. Chief Medical Officer Rodman David Malcom reported option and stock transactions in company shares. On February 17, 2026, he exercised a stock option for 417 shares of common stock at $15.44 per share and then sold 417 shares at $27.59 per share.

After these transactions, he directly owned 44,089 shares of common stock and 5,417 stock options. The filing states the trades were carried out under a Rule 10b5-1 trading plan adopted on October 6, 2025, indicating they were pre-arranged rather than discretionary trades.

Insider Trade Summary

Net Seller: 417 shares ($11,505)

Net Sell 3 txns

Insider Rodman David Malcom

Role Chief Medical Officer

Sold 417 shs ($12K)

Type	Security	Shares	Price	Value
Exercise	Stock Option	417	$0.00	--
Exercise	Common Stock	417	$15.44	$6K
Sale	Common Stock	417	$27.59	$12K

Holdings After Transaction: Stock Option — 5,417 shares (Direct); Common Stock — 44,506 shares (Direct)

Footnotes (1)

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodman David Malcom

(Last) (First) (Middle)

150 N. RADNOR CHESTER RD.

SUITE F200

(Street)

RADNOR PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		M(1)		417	A	$15.44	44,506	D
Common Stock	02/17/2026		S(1)		417	D	$27.59	44,089	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$15.44	02/17/2026		M(1)			417	(2)	03/17/2033	Common Stock	417	$0	5,417	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

2. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Mineralys Therapeutics (MLYS) report for Rodman David Malcom?

Rodman David Malcom reported exercising 417 stock options and selling 417 common shares on February 17, 2026. The option exercise price was $15.44 per share and the sale price was $27.59 per share, all under a pre-arranged Rule 10b5-1 trading plan.

How many Mineralys Therapeutics (MLYS) shares does the CMO own after the Form 4?

After the reported transactions, the Chief Medical Officer directly owned 44,089 shares of Mineralys Therapeutics common stock. He also beneficially owned 5,417 stock options, reflecting his remaining derivative position following the exercise of 417 options on February 17, 2026.

Were the Mineralys Therapeutics (MLYS) insider trades under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on October 6, 2025. Such plans allow insiders to pre-schedule trades, helping separate their transactions from day-to-day discretionary trading decisions.

What prices were involved in the Mineralys Therapeutics (MLYS) CMO’s Form 4 trades?

The stock option was exercised at $15.44 per share, converting into 417 common shares. Those 417 common shares were then sold at $27.59 per share. Both transactions occurred on February 17, 2026, according to the Form 4 filing details.

What derivative securities did the Mineralys Therapeutics (MLYS) CMO retain?

Following the reported exercise, the Chief Medical Officer held 5,417 stock options. The option has a $15.44 exercise price, became exercisable over time based on its vesting schedule, and carries an expiration date of March 17, 2033, as described in the filing.

How does the stock option for Mineralys Therapeutics (MLYS) vest for the CMO?

The stock option vested 25% of its underlying shares on the first anniversary of the grant date. The remaining shares vest in 36 substantially equal monthly installments thereafter, creating a gradual vesting pattern aligned with longer-term service.